{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T15:54:30Z","timestamp":1784735670066,"version":"3.55.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T00:00:00Z","timestamp":1766966400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T00:00:00Z","timestamp":1769644800000},"content-version":"vor","delay-in-days":31,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["16LW0298"],"award-info":[{"award-number":["16LW0298"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["16LW0298"],"award-info":[{"award-number":["16LW0298"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Krebsgesellschaft Mecklenburg-Vorpommern"},{"name":"Lieselotte Beutel Stiftung"},{"name":"Rostock University Medical Center","award":["FORUN"],"award-info":[{"award-number":["FORUN"]}]},{"name":"Rostock School of Oncology","award":["Medical Scientist Fellowship"],"award-info":[{"award-number":["Medical Scientist Fellowship"]}]},{"name":"Comprehensive Cancer Center Mecklenburg-Vorpommern","award":["Clinician Scientist Fellowship"],"award-info":[{"award-number":["Clinician Scientist Fellowship"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Precis. Onc."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The BCL-2 inhibitor venetoclax (VEN) has emerged as an important therapeutic backbone for hematological malignancies, but secondary resistance is a major challenge. In acute lymphoblastic leukemia (ALL), early clinical trials promise high efficacy as well. However, relapse is observed frequently, and so far, only a few resistance-inducing mechanisms have been discussed. We employed KMT2A-rearranged ALL cell lines and xenograft models to elucidate mechanisms of VEN resistance. Targeted DNA and mRNA sequencing, single-cell mRNAseq, as well as protein expression analyses were conducted. All models initially responded well but finally displayed secondary resistance. Novel as well as previously known pathogenic variants in tumor suppressor\n                    <jats:italic>TP53<\/jats:italic>\n                    as well as pro-apoptotic molecule\n                    <jats:italic>BAX<\/jats:italic>\n                    , but not\n                    <jats:italic>BCL2<\/jats:italic>\n                    , were observed. Gene and protein expression studies demonstrated multifarious changes in resistant cells, with high inter- and intra-model heterogeneity. Finally, single-cell RNA sequencing revealed a likely contribution of the tumor microenvironment in the development of VEN resistance, as indicated by modulation of genes involved in cell-cell interaction and humoral signaling in resistance-specific clusters. Our data demonstrate and characterize the rise of VEN resistance in KMT2A-rearranged ALL models, suggesting that relapse must be expected in the clinical setting and that multifactorial processes are involved in this process.\n                  <\/jats:p>","DOI":"10.1038\/s41698-025-01249-1","type":"journal-article","created":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T03:44:38Z","timestamp":1766979878000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Venetoclax resistance in preclinical KMT2A-rearranged acute lymphoblastic leukemia models is characterized by high inter- and intra-model heterogeneity"],"prefix":"10.1038","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3500-7072","authenticated-orcid":false,"given":"Anna","family":"Richter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lea","family":"Kinsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Lange","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nares","family":"Trakooljul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frieder","family":"Hadlich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anett","family":"Sekora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gudrun","family":"Knuebel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saskia","family":"Krohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Busch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Schreiber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Kumstel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Wimmers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugo","family":"Murua Escobar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Junghanss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,29]]},"reference":[{"key":"1249_CR1","doi-asserted-by":"publisher","first-page":"4134","DOI":"10.1200\/JCO.2014.56.3247","volume":"32","author":"MS Topp","year":"2014","unstructured":"Topp, M. S. et al. Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia. J. Clin. Oncol. 32, 4134\u20134140 (2014).","journal-title":"J. Clin. Oncol."},{"key":"1249_CR2","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude, S. L. et al. Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. N. Engl. J. Med. 378, 439\u2013448 (2018).","journal-title":"N. Engl. J. Med."},{"key":"1249_CR3","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1182\/blood-2001-12-0181","volume":"100","author":"OG Ottmann","year":"2002","unstructured":"Ottmann, O. G. et al. A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood 100, 1965\u20131971 (2002).","journal-title":"Blood"},{"key":"1249_CR4","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1182\/blood-2018-02-791350","volume":"132","author":"R Valentin","year":"2018","unstructured":"Valentin, R., Grabow, S. & Davids, M. S. The rise of apoptosis: targeting apoptosis in hematologic malignancies. Blood 132, 1248\u20131264 (2018).","journal-title":"Blood"},{"key":"1249_CR5","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo, C. D. et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N. Engl. J. Med. 383, 617\u2013629 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1249_CR6","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1513257","volume":"374","author":"AW Roberts","year":"2016","unstructured":"Roberts, A. W. et al. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N. Engl. J. Med. 374, 311\u2013322 (2016).","journal-title":"N. Engl. J. Med."},{"key":"1249_CR7","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1182\/blood.2019004205","volume":"135","author":"P Blombery","year":"2020","unstructured":"Blombery, P. et al. Multiple BCL2 mutations cooccurring with Gly101Val emerge in chronic lymphocytic leukemia progression on venetoclax. Blood 135, 773\u2013777 (2020).","journal-title":"Blood"},{"key":"1249_CR8","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1182\/blood.2022016090","volume":"141","author":"DM Moujalled","year":"2023","unstructured":"Moujalled, D. M. et al. Acquired mutations in BAX confer resistance to BH3-mimetic therapy in acute myeloid leukemia. Blood 141, 634\u2013644 (2023).","journal-title":"Blood"},{"key":"1249_CR9","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1182\/blood.2019003988","volume":"135","author":"CD DiNardo","year":"2020","unstructured":"DiNardo, C. D. et al. Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML. Blood 135, 791\u2013803 (2020).","journal-title":"Blood"},{"key":"1249_CR10","doi-asserted-by":"publisher","first-page":"E202","DOI":"10.1002\/ajh.25146","volume":"93","author":"B Chyla","year":"2018","unstructured":"Chyla, B. et al. Genetic biomarkers of sensitivity and resistance to venetoclax monotherapy in patients with relapsed acute myeloid leukemia. Am. J. Hematol. 93, E202\u2013E205 (2018).","journal-title":"Am. J. Hematol."},{"key":"1249_CR11","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1158\/2159-8290.CD-19-0125","volume":"9","author":"T Nechiporuk","year":"2019","unstructured":"Nechiporuk, T. et al. The TP53 apoptotic network is a primary mediator of resistance to BCL2 inhibition in AML cells. Cancer Discov. 9, 910\u2013925 (2019).","journal-title":"Cancer Discov."},{"key":"1249_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-41229-2","volume":"14","author":"J Ebner","year":"2023","unstructured":"Ebner, J. et al. ABCC1 and glutathione metabolism limit the efficacy of BCL-2 inhibitors in acute myeloid leukemia. Nat. Commun. 14, 5709 (2023).","journal-title":"Nat. Commun."},{"key":"1249_CR13","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1158\/2159-8290.CD-20-1465","volume":"11","author":"VA Pullarkat","year":"2021","unstructured":"Pullarkat, V. A. et al. Venetoclax and navitoclax in combination with chemotherapy in patients with relapsed or refractory acute lymphoblastic leukemia and lymphoblastic lymphoma. Cancer Discov. 11, 1440\u20131453 (2021).","journal-title":"Cancer Discov."},{"key":"1249_CR14","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1182\/bloodadvances.2023012231","volume":"8","author":"NJ Short","year":"2024","unstructured":"Short, N. J. et al. A phase 1\/2 study of mini-hyper-CVD plus venetoclax in patients with relapsed\/refractory acute lymphoblastic leukemia. Blood Adv. 8, 909\u2013915 (2024).","journal-title":"Blood Adv."},{"key":"1249_CR15","doi-asserted-by":"crossref","unstructured":"Richter, A. et al. Effective tumor cell abrogation via Venetoclax-mediated BCL-2 inhibition in KMT2A-rearranged acute B-lymphoblastic leukemia. Cell Death Discov. 8 (2022).","DOI":"10.1038\/s41420-022-01093-3"},{"key":"1249_CR16","doi-asserted-by":"crossref","unstructured":"Seyfried, F. et al. Prediction of venetoclax activity in precursor B-ALL by functional assessment of apoptosis signaling. Cell Death Dis. 10 (2019).","DOI":"10.1038\/s41419-019-1801-0"},{"key":"1249_CR17","doi-asserted-by":"publisher","first-page":"2715","DOI":"10.1016\/j.celrep.2015.12.003","volume":"13","author":"JM Benito","year":"2015","unstructured":"Benito, J. M. et al. MLL-rearranged acute lymphoblastic leukemias activate BCL-2 through H3K79 methylation and are sensitive to the BCL-2-specific antagonist ABT-199. Cell Rep. 13, 2715\u20132727 (2015).","journal-title":"Cell Rep."},{"key":"1249_CR18","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1038\/sj.onc.1203434","volume":"19","author":"AN Bullock","year":"2000","unstructured":"Bullock, A. N., Henckel, J. & Fersht, A. R. Quantitative analysis of residual folding and DNA binding in mutant p53 core domain: definition of mutant states for rescue in cancer therapy. Oncogene 19, 1245\u20131256 (2000).","journal-title":"Oncogene"},{"key":"1249_CR19","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1038\/ncb1802","volume":"10","author":"M Jansson","year":"2008","unstructured":"Jansson, M. et al. Arginine methylation regulates the p53 response. Nat. Cell Biol. 10, 1431\u20131439 (2008).","journal-title":"Nat. Cell Biol."},{"key":"1249_CR20","doi-asserted-by":"publisher","first-page":"8424","DOI":"10.1073\/pnas.1431692100","volume":"100","author":"S Kato","year":"2003","unstructured":"Kato, S. et al. Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis. Proc. Natl. Acad. Sci. USA. 100, 8424\u20138429 (2003).","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"1249_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/srep24097","volume":"6","author":"X Tian","year":"2016","unstructured":"Tian, X., Dai, S., Sun, J., Jiang, S. & Jiang, Y. Association between TP53 Arg72Pro polymorphism and leukemia risk: a meta-analysis of 14 case-control studies. Sci. Rep. 6, 24097 (2016).","journal-title":"Sci. Rep."},{"key":"1249_CR22","doi-asserted-by":"publisher","unstructured":"Cheung, L. C. et al. Preclinical efficacy of azacitidine and venetoclax for infant KMT2A-rearranged acute lymphoblastic leukemia reveals a new therapeutic strategy. Leukemia https:\/\/doi.org\/10.1038\/s41375-022-01746-3 (2022).","DOI":"10.1038\/s41375-022-01746-3"},{"key":"1249_CR23","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1182\/blood-2016-03-707414","volume":"128","author":"SL Khaw","year":"2016","unstructured":"Khaw, S. L. et al. Venetoclax responses of pediatric ALL xenografts reveal sensitivity of MLL-rearranged leukemia. Blood 128, 1382\u20131395 (2016).","journal-title":"Blood"},{"key":"1249_CR24","doi-asserted-by":"publisher","first-page":"692880","DOI":"10.3389\/fmolb.2021.692880","volume":"8","author":"S Liu","year":"2021","unstructured":"Liu, S. et al. RUNX1 Upregulates CENPE to promote leukemic cell proliferation. Front. Mol. Biosci. 8, 692880 (2021).","journal-title":"Front. Mol. Biosci."},{"key":"1249_CR25","doi-asserted-by":"publisher","first-page":"4019","DOI":"10.1038\/onc.2014.332","volume":"34","author":"T Chen","year":"2015","unstructured":"Chen, T., Sun, Y., Ji, P., Kopetz, S. & Zhang, W. Topoisomerase II\u03b1 in chromosome instability and personalized cancer therapy. Oncogene 34, 4019\u20134031 (2015).","journal-title":"Oncogene"},{"key":"1249_CR26","doi-asserted-by":"crossref","unstructured":"Jia, Y. et al. Identification of NCAPG as an essential gene for neuroblastoma employing CRISPR-Cas9 Screening Database and experimental verification. Int. J. Mol. Sci. 24 (2023).","DOI":"10.3390\/ijms241914946"},{"key":"1249_CR27","doi-asserted-by":"publisher","first-page":"4148","DOI":"10.1016\/j.febslet.2012.10.012","volume":"586","author":"M-R Gwon","year":"2012","unstructured":"Gwon, M.-R., Cho, J. H. & Kim, J.-R. Mitotic centromere-associated kinase (MCAK\/Kif2C) regulates cellular senescence in human primary cells through a p53-dependent pathway. FEBS Lett. 586, 4148\u20134156 (2012).","journal-title":"FEBS Lett."},{"key":"1249_CR28","doi-asserted-by":"publisher","first-page":"109113","DOI":"10.1016\/j.biopha.2019.109113","volume":"117","author":"J Qi","year":"2019","unstructured":"Qi, J. et al. Selective inhibition of Aurora A and B kinases effectively induces cell cycle arrest in t(8;21) acute myeloid leukemia. Biomed. Pharmacother. 117, 109113 (2019).","journal-title":"Biomed. Pharmacother."},{"key":"1249_CR29","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3233\/CBM-203170","volume":"35","author":"M Shi","year":"2022","unstructured":"Shi, M. et al. Upregulated mitosis-associated genes CENPE, CENPF, and DLGAP5 predict poor prognosis and chemotherapy resistance of Acute Myeloid Leukemia. Cancer biomarkers 35, 11\u201325 (2022).","journal-title":"Cancer biomarkers"},{"key":"1249_CR30","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1083\/jcb.201803003","volume":"218","author":"AK Byrum","year":"2019","unstructured":"Byrum, A. K. et al. Mitotic regulators TPX2 and Aurora A protect DNA forks during replication stress by counteracting 53BP1 function. J. Cell Biol. 218, 422\u2013432 (2019).","journal-title":"J. Cell Biol."},{"key":"1249_CR31","doi-asserted-by":"publisher","first-page":"2360","DOI":"10.1182\/blood.2021011247","volume":"138","author":"Y Li","year":"2021","unstructured":"Li, Y. et al. DYRK1a mediates BAFF-induced noncanonical NF-\u03baB activation to promote autoimmunity and B-cell leukemogenesis. Blood 138, 2360\u20132371 (2021).","journal-title":"Blood"},{"key":"1249_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-49882-x","volume":"15","author":"GP Grothusen","year":"2024","unstructured":"Grothusen, G. P. et al. DCAF15 control of cohesin dynamics sustains acute myeloid leukemia. Nat. Commun. 15, 5604 (2024).","journal-title":"Nat. Commun."},{"key":"1249_CR33","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1080\/10428194.2017.1387906","volume":"59","author":"L Peng","year":"2018","unstructured":"Peng, L. et al. Structural maintenance of chromosomes 4 is required for leukemia stem cell maintenance in MLL-AF9 induced acute myeloid leukemia. Leuk. Lymphoma 59, 2423\u20132430 (2018).","journal-title":"Leuk. Lymphoma"},{"key":"1249_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cells11010150","volume":"11","author":"A Richter","year":"2022","unstructured":"Richter, A. et al. The molecular subtype of adult acute lymphoblastic leukemia samples determines the engraftment site and proliferation kinetics in patient-derived xenograft models. Cells 11, 1\u201322 (2022).","journal-title":"Cells"},{"key":"1249_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15252\/emmm.201809443","volume":"10","author":"P Richter-Pecha\u0144ska","year":"2018","unstructured":"Richter-Pecha\u0144ska, P. et al. PDX models recapitulate the genetic and epigenetic landscape of pediatric T-cell leukemia. EMBO Mol. Med. 10, 1\u201313 (2018).","journal-title":"EMBO Mol. Med."},{"key":"1249_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13046-021-01835-8","volume":"40","author":"AC Uzozie","year":"2021","unstructured":"Uzozie, A. C. et al. PDX models reflect the proteome landscape of pediatric acute lymphoblastic leukemia but divert in select pathways. J. Exp. Clin. Cancer Res. 40, 1\u201324 (2021).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"1249_CR37","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1002\/ijc.28170","volume":"133","author":"J Woiterski","year":"2013","unstructured":"Woiterski, J. et al. Engraftment of low numbers of pediatric acute lymphoid and myeloid leukemias into NOD\/SCID\/IL2Rc\u03b3null mice reflects individual leukemogenecity and highly correlates with clinical outcome. Int. J. Cancer 133, 1547\u20131556 (2013).","journal-title":"Int. J. Cancer"},{"key":"1249_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-024-06864-7","volume":"15","author":"S Enzenm\u00fcller","year":"2024","unstructured":"Enzenm\u00fcller, S. et al. Venetoclax resistance in acute lymphoblastic leukemia is characterized by increased mitochondrial activity and can be overcome by co-targeting oxidative phosphorylation. Cell Death Dis. 15, 475 (2024).","journal-title":"Cell Death Dis."},{"key":"1249_CR39","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1182\/blood-2016-02-699363","volume":"130","author":"R Karjalainen","year":"2017","unstructured":"Karjalainen, R. et al. JAK1\/2 and BCL2 inhibitors synergize to counteract bone marrow stromal cell-induced protection of AML. Blood 130, 789\u2013802 (2017).","journal-title":"Blood"},{"key":"1249_CR40","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.bcmd.2015.07.001","volume":"55","author":"AM G\u00f3mez","year":"2015","unstructured":"G\u00f3mez, A. M. et al. Chemokines and relapses in childhood acute lymphoblastic leukemia: a role in migration and in resistance to antileukemic drugs. Blood Cells. Mol. Dis. 55, 220\u2013227 (2015).","journal-title":"Blood Cells. Mol. Dis."},{"key":"1249_CR41","doi-asserted-by":"publisher","first-page":"2808","DOI":"10.1182\/blood-2016-06-720490","volume":"128","author":"D Chiron","year":"2016","unstructured":"Chiron, D. et al. Rational targeted therapies to overcome microenvironment-dependent expansion of mantle cell lymphoma. Blood 128, 2808\u20132818 (2016).","journal-title":"Blood"},{"key":"1249_CR42","doi-asserted-by":"publisher","first-page":"e52798","DOI":"10.1371\/journal.pone.0052798","volume":"7","author":"N Terziyska","year":"2012","unstructured":"Terziyska, N. et al. In vivo imaging enables high resolution preclinical trials on patients\u2019 leukemia cells growing in mice. PLoS ONE 7, e52798 (2012).","journal-title":"PLoS ONE"},{"key":"1249_CR43","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s13045-018-0607-3","volume":"11","author":"C Roolf","year":"2018","unstructured":"Roolf, C. et al. Decitabine demonstrates antileukemic activity in B cell precursor acute lymphoblastic leukemia with MLL rearrangements. J. Hematol. Oncol. 11, 62 (2018).","journal-title":"J. Hematol. Oncol."},{"key":"1249_CR44","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-019-5411-0","volume":"19","author":"A Richter","year":"2019","unstructured":"Richter, A. et al. Combined Casein Kinase II inhibition and epigenetic modulation in acute B-lymphoblastic leukemia. BMC Cancer 19, 202 (2019).","journal-title":"BMC Cancer"},{"key":"1249_CR45","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-020-6650-9","volume":"20","author":"A Richter","year":"2020","unstructured":"Richter, A. et al. Influence of Casein kinase II inhibitor CX-4945 on BCL6-mediated apoptotic signaling in B-ALL in vitro and in vivo. BMC Cancer 20, 184 (2020).","journal-title":"BMC Cancer"},{"key":"1249_CR46","unstructured":"Marques de Almeida, F. et al. nf-core\/scrnaseq: 4.0.0. at (2025)."},{"key":"1249_CR47","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/s41587-023-01767-y","volume":"42","author":"Y Hao","year":"2024","unstructured":"Hao, Y. et al. Dictionary learning for integrative, multimodal and scalable single-cell analysis. Nat. Biotechnol. 42, 293\u2013304 (2024).","journal-title":"Nat. Biotechnol."},{"key":"1249_CR48","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-14-128","volume":"14","author":"EY Chen","year":"2013","unstructured":"Chen, E. Y. et al. Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool. BMC Bioinformatics 14, 128 (2013).","journal-title":"BMC Bioinformatics"},{"key":"1249_CR49","doi-asserted-by":"publisher","first-page":"W90","DOI":"10.1093\/nar\/gkw377","volume":"44","author":"MV Kuleshov","year":"2016","unstructured":"Kuleshov, M. V. et al. Enrichr: a comprehensive gene set enrichment analysis web server 2016 update. Nucleic Acids Res. 44, W90\u2013W97 (2016).","journal-title":"Nucleic Acids Res."},{"key":"1249_CR50","doi-asserted-by":"publisher","first-page":"e90","DOI":"10.1002\/cpz1.90","volume":"1","author":"Z Xie","year":"2021","unstructured":"Xie, Z. et al. Gene set knowledge discovery with Enrichr. Curr. Protoc. 1, e90 (2021).","journal-title":"Curr. Protoc."}],"container-title":["npj Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41698-025-01249-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-025-01249-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-025-01249-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T13:04:39Z","timestamp":1769691879000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41698-025-01249-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,29]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1249"],"URL":"https:\/\/doi.org\/10.1038\/s41698-025-01249-1","relation":{},"ISSN":["2397-768X"],"issn-type":[{"value":"2397-768X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,29]]},"assertion":[{"value":"20 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"47"}}